70 research outputs found
Predicting Pancreas Cell Fate Decisions and Reprogramming with a Hierarchical Multi-Attractor Model
Cell fate reprogramming, such as the generation of insulin-producing β cells from other pancreas cells, can be achieved by external modulation of key transcription factors. However, the known gene regulatory interactions that form a complex network with multiple feedback loops make it increasingly difficult to design the cell reprogramming scheme because the linear regulatory pathways as schemes of causal influences upon cell lineages are inadequate for predicting the effect of transcriptional perturbation. However, sufficient information on regulatory networks is usually not available for detailed formal models. Here we demonstrate that by using the qualitatively described regulatory interactions as the basis for a coarse-grained dynamical ODE (ordinary differential equation) based model, it is possible to recapitulate the observed attractors of the exocrine and β, δ, α endocrine cells and to predict which gene perturbation can result in desired lineage reprogramming. Our model indicates that the constraints imposed by the incompletely elucidated regulatory network architecture suffice to build a predictive model for making informed decisions in choosing the set of transcription factors that need to be modulated for fate reprogramming
Small-molecule inhibitors of the cystic fibrosis transmembrane conductance regulator increase pancreatic endocrine cell development in rat and mouse
Geometric consistency and stability of consumer-grade digital cameras for accurate spatial measurement
This is a journal article. It was published in the journal, The Photogrammetric Record [© Remote Sensing and Photogrammetry Society and Blackwell Publishing Ltd] and the definitive version is available at: http://www3.interscience.wiley.com/journal/118539355/homeIt is known that uncertain internal geometry of consumer-grade
digital cameras limits the accuracy of data that can be extracted. These
cameras can be calibrated, but the validity of calibration data over a
period of time should be carefully assessed before subsequent
photogrammetric measurement. This paper examines the geometric
stability and manufacturing consistency of a typical low-cost digital
camera (Nikon Coolpix 5400) by estimating the degree of similarity
between interior orientation parameters (IOP), established over a oneyear
period. Digital elevation models (DEMs) are extracted with
differing interior orientation parameters (IOP) sets and accuracies are
compared using data obtained from seven identical cameras. An
independent self-calibrating bundle adjustment (GAP) and the Leica
Photogrammetry Suite (LPS) software were used to provide these datasets.
Results are presented that indicate the potential of these cameras to
maintain their internal geometry in terms of temporal stability and
manufacturing consistency. This study also identifies residual systematic
error surfaces or “domes”, discernible in “DEMs of difference”. These
are caused by slightly inaccurately estimated lens distortion parameters,
which effectively constrain the accuracies achievable with this class of
sensor
Multiple Phenotypes in Adult Mice following Inactivation of the Coxsackievirus and Adenovirus Receptor (Car) Gene
To determine the normal function of the Coxsackievirus and Adenovirus Receptor (CAR), a protein found in tight junctions and other intercellular complexes, we constructed a mouse line in which the CAR gene could be disrupted at any chosen time point in a broad spectrum of cell types and tissues. All knockouts examined displayed a dilated intestinal tract and atrophy of the exocrine pancreas with appearance of tubular complexes characteristic of acinar-to-ductal metaplasia. The mice also exhibited a complete atrio-ventricular block and abnormal thymopoiesis. These results demonstrate that CAR exerts important functions in the physiology of several organs in vivo
Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council
Adult rat liver cells transdifferentiated with lentiviral IPF1 vectors reverse diabetes in mice: an ex vivo gene therapy approach
Co-benefits: Taking a multidisciplinary approach
Most environmental policies are meant to achieve a single goal such as reducing pollution, preserving ecosystems or mitigating climate change. Yet environmental issues are frequently interlinked and approaches that exploit these linkages can deliver more than one desirable outcome. The collection of benefits accruing to actions linking climate change and other development priorities (e.g., reducing local pollution) are known as "co-benefits". Over the past two decades, a growing number of studies have demonstrated that an integrated or co-benefits approach could prove more cost effective than managing climate and development issues in isolation, but policies reflecting this integration have tended to lag behind research. This article argues that a multidisciplinary approach will be needed to bring policies in line with research on co-benefits
- …